Acarix

Acarix EBITDA per Share

The EBITDA per Share of Acarix (ACARIX.ST) as of Nov 12, 2026 is -0.04 SEK. In the previous year, EBITDA per Share was -0.06 SEK — a change of -31.06% (higher).

EBITDA per Share

-0.04SEK

YoY

-31.06%

Last updated:

EBITDA per Share of Acarix is 2025 -0.04 SEK. EBITDA per Share of Acarix was 2024 -0.06 SEK. It decreases by -31.06% higher compared to the previous year.

The Acarix EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.84 SEK
Jan 1, 2019
-0.97 SEK
Jan 1, 2020
-0.47 SEK
Jan 1, 2021
-0.21 SEK
Jan 1, 2022
-0.28 SEK
Jan 1, 2023
-0.12 SEK
Jan 1, 2024
-0.06 SEK
Jan 1, 2025
-0.04 SEK
The Acarix EBITDA per Share history
YEAREBITDA per ShareYoY
-0.04SEK-31.06%
-0.06SEK-49.27%
-0.12SEK-56.15%
-0.28SEK+34.18%
-0.21SEK-56.38%
-0.47SEK-51.41%
-0.97SEK+15.61%
-0.84SEK+14.41%
-0.73SEK-37.18%
-1.16SEK+52.42%
-0.76SEK+3,760.19%
-0.02SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acarix Stock analysis

What does Acarix do? Acarix AB generates revenue through the sale of its primary medical device, the CADScor System, which utilizes phonocardiography for coronary artery disease monitoring. The system is designed for use by physicians, nurses, and laboratory technicians in clinical settings, featuring a chest patch with a recording head positioned at the fourth left intercostal space and a sensor on the sternum. Patients undergo a two-minute heart sound recording guided by audio cues and display instructions, after which the CAD-score is calculated and displayed for diagnostic purposes. The company's business model relies on direct sales of the CADScor System to healthcare providers, including hospitals and diagnostic laboratories, where the device is used for non-invasive rule-out diagnosis of coronary artery disease. The system's unique phonocardiography technique and algorithm-based scoring provide a streamlined diagnostic process, reducing the need for more invasive procedures and appealing to medical professionals seeking efficient diagnostic tools. Acarix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acarix stock

EBITDA per Share of Acarix is -0.04 SEK in 2025.

EBITDA per Share of Acarix changed from -0.06 SEK to -0.04 SEK, representing a -31.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Acarix since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Acarix

All Key Metrics — Acarix